title: An audit of postoperative radiotherapy after non-curative resection for cancer of the oesophagus.
abstract: OBJECTIVE
  The role of postoperative radiotherapy (PORT) after non-curative resections for cancer oesophagus is not well defined. A policy of offering PORT after non-curative resections for cancer oesophagus has been followed at our institution, and we report an audit of our experience.
  
  
  METHODS
  Between March 1990 and September 2002, 139 patients underwent resections for cancer oesophagus. Of these, 86 patients received PORT to a dose of 45-50.4 Gy/25-28 fractions. Eleven of these patients also received concurrent and adjuvant 5-fluorouracil (5-FU). Disease-free survival and overall survival were computed from the day of surgery using the Kaplan-Meier method.
  
  
  RESULTS
  Seventy-six per cent (65/86) of patients had squamous cell carcinoma and 69% (59/86) of patients had tumours in the lower-third of the oesophagus. The median interval between surgery and PORT was 41 days, and 93% of patients received doses as planned. Strictures at the anastomotic site and ulcerations in the stomach mucosa were seen in 17% and 5% of patients, respectively. The median and 5-year disease-free survival was 12 months (95% CI 9.9-14.1) and 14%; whereas the median and 5-year overall survival was 17 months (95% CI 12.4-21.6) and 17%, respectively. Local and distant failures were seen in 29% and 45% of patients, respectively.
  
  
  CONCLUSIONS
  PORT, after a non-curative resection of cancer oesophagus, is well tolerated with acceptable morbidity and survival.
authors.affiliation: Department of Radiotherapy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. shaleenkr@yahoo.com
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.forename: K
authors.initials: K
authors.lastname: Dimri
authors.forename: P
authors.initials: P
authors.lastname: Balachandran
authors.forename: A
authors.initials: A
authors.lastname: Kumar
authors.forename: P
authors.initials: P
authors.lastname: Lal
authors.forename: S S
authors.initials: SS
authors.lastname: Sikora
authors.forename: N
authors.initials: N
authors.lastname: Rastogi
authors.forename: R
authors.initials: R
authors.lastname: Saxena
authors.forename: N R
authors.initials: NR
authors.lastname: Datta
authors.forename: S
authors.initials: S
authors.lastname: Ayyagari
authors.forename: V K
authors.initials: VK
authors.lastname: Kapoor
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011878:Radiotherapy / Q000009:adverse effects; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D005472:Fluorouracil